Importantly, data from clinical populations suggest that GLP‐1 RA therapy may actually result in muscle atrophy as dulaglutide was reported to have a significantly negative effect on skeletal muscle mass in people with T2DM on haemodialysis. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.